The Daily Biotech Pulse: Adcom Backs Merck’s Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours:
Jefferies Upgrades Immunogen to Buy, Raises Price Target to $12
Jefferies analyst Kelly Shi upgrades Immunogen (NASDAQ:IMGN) from Hold to Buy and raises the price target from $7 to $12.
